Thailand Elite’s Real Estate Partnership Set to Attract Foreign Investors Keen on Relocating and Owning Property in Thailand
Thailand’s sought-after Thailand Elite Residence Program which saw a sharp spike in applications throughout the Covid-19 pandemic in 2020, is set to be even more attractive to foreign investors following a new partnership with more than 10 leading real estate developers in Thailand as part of its Elite Flexible One (EFO) offering.
According to Mr. Somchai Soongswang, President of Thailand Privilege Card Co., Ltd., the operator of Thailand Elite Card, “This pivotal partnership is expected to boost the property sector in Thailand through creating a multi-faceted return for international investors. The EFO option under the privileged entry visa program is of particular interest for applicants who are keen on investing in property either for residence or as an investment. The investors not only gain a return on their property investment but the inherent business & lifestyle benefits of Thai residence”
Each participating developer has a broad and deep selection of available property projects for foreign investors to choose from. Property purchases valued at the minimum of 10 million baht, will afford the buyer consideration for membership of Elite Flexible One, a five-year privilege entry visa – a similar five-year visa (Elite Easy Access) would normally cost THB 600,000 or approximately USD 19,000. The membership not only offers ease of entry into Thailand along with a wide range of VIP benefits, but also business and lifestyle services and rewards as offered by the developer partners to ensure members get the most out of residing in Thailand.
Thailand’s property market has long been considered stable and attractive, both in the form of rental yields, which can reach 8% in Bangkok, as well as capital gains on property value, with return on investment exceeding 10% per annum. Property analysts have predicted that the luxury housing market will be one of the fastest recovering segments as lockdown restrictions eased, with further market recovery expected to continue upon the resumption of freer international travel.
As condo developers are focused on clearing unsold inventory at pre-launch prices, these ready-to-move-into projects offer impressive value. Thai luxury real estate therefore represents a remarkable investment opportunity. Among the developers participating in the limited two-year scheme are well known names such as Sansiri, Ananda Development, AP (Thailand), Origin Property, Raimon Land and Charn Issara Development. There are over 45 projects available including those located in Bangkok’s upscale residential areas which includes Sukhumvit, Silom, Sathorn, and Asoke.
According to Dominic Volek, Group Head of Private Clients at Henley & Partners, the global concessionaire for Thailand Elite, “Savvy investors are now realizing that diversification is as relevant to lifestyle planning as it is to wealth management. As they reevaluate their priorities and seek alternative options for residence, the Thailand Elite Residence Program is often a top choice as it is a safe, prosperous country with an excellent quality of life.”
Since Henley & Partners became the official global concessionaire, the Thailand Elite Residence Program has expanded considerably and now has over 13,000 members. The first of its kind worldwide, the program is managed by Thailand Privilege Card Co. Ltd and offers applicants privilege entry visas, which include a wide range of VIP benefits. The program provides a multiple-entry visa to qualified applicants, allowing them to visit and reside in Thailand for a period of between five and twenty years, at a one-time cost of between THB 600,000 (approximately USD 19,000) and THB 2.14 million (approximately USD 68,000), depending on the option chosen. Benefits include airport limo services and lounge access, expedited immigration formalities, access to world-class healthcare services, dedicated concierge, and various privileges across hotels, shopping centers, golf courses, and more.
Henley & Partners caters to all clients interested in the program, either in person, via one of its offices globally, or virtually, via its online portal, thailandelite-direct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005032/en/
Contact information
Media
Alina Morais
Head of Public Relations, Southeast Asia
alina.morais@henleyglobal.com
+65 9295 4792
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom